Compare Appian Corp (APPN) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Appian Corp vs Sanofi SA — how do they compare? Appian Corp trades at $35.5 (market cap $2.54B), while Sanofi SA trades at $43.7 (market cap $104.30B). The key difference: Sanofi SA is far larger — about 41.1× Appian Corp's market cap, and Sanofi SA pays a 5.55% dividend while Appian Corp pays none. Which is the better fit depends on your goals.
| APPN | SNY | |
|---|---|---|
Market Cap | $2.54B | $104.30B |
Sector | Technology | Health |
52-Week High | $45.64 | $52.34 |
52-Week Low | $18.72 | $41.33 |
Enterprise Value | $2.67B | $124.19B |
Dividend Yield | — | 5.55% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Appian Corp
Appian Corp provides a low-code software development platform as a service that enables organizations to rapidly develop powerful and unique applications. With its platform, organizations can rapidly and easily design, build and implement powerful, enterprise-grade custom applications through intuitive, visual interface with little or no coding required. The company's customers use applications built on its low-code platform to launch new business lines, automate vital employee workflows, manage complex trading platforms, accelerate drug development and build procurement systems. The group generates a majority of its revenue from the domestic market. It serves various industries such as education.
Read more on APPN →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
